Assessment of the benefit–risk balance of SGLT2 inhibitors: Commentary on a new ‘French paradox’ - 15/08/19
Doi : 10.1016/j.diabet.2019.04.001
A.J. Scheen a, ⁎ 
, P. Darmon b : Coordinator of the writing committee of the position statement by the SFD, H. Hanaire c : President of the SFD
, P. Darmon b : Coordinator of the writing committee of the position statement by the SFD, H. Hanaire c : President of the SFDon behalf of the writing committee of the position statement by the French-Speaking Society of Diabetes (SFD)1
a Service de diabétologie, nutrition et maladies métaboliques, CHU de Liège, Liège université, Liège, Belgium
b Pôle endocrinologie, nutrition, diabète et obésité, hôpital de la Conception, Aix-Marseille université, Inserm, Inra, C2VN, 13005 Marseille, France
c Service de diabétologie, CHU Rangueil, 31400 Toulouse, France
⁎Corresponding author.
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Keywords : SGLT2 inhibitors, ‘French paradox’
Il testo completo di questo articolo è disponibile in PDF.
Mappa
© 2019
Elsevier Masson SAS. Tutti i diritti riservati.
Vol 45 - N° 4
P. 319-321 - settembre 2019 Ritorno al numero
Articolo precedente
- Editorial board
- Digital diabetes: Perspectives for diabetes prevention, management and research
- G. Fagherazzi, P. Ravaud
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.